Continuing his weeklong series featuring biotech companies with blockbuster drug potential, Cramer recommended Exact Sciences (EXAS), a company working on a non-invasive test to detect colorectal cancer.
Cramer said that only 40% of new colorectal cancer cases are detected early, in part to the reluctance of patients aged 50 and over being reluctant to get regular, and often uncomfortable, colonoscopies. He said the survival rate for colorectal cancer is 91% if detected early, but only 11% if the cancer is not found until it spreads throughout the body.
Enter Exact Sciences, with a new colorectal cancer test that only involves mailing a stool sample to a lab. The test is currently preparing for Phase III clinical trials and is likely to seek FDA approval in 2012. While Exact Sciences' test is not a replacement for colonoscopies, given how many patients avoid the test, Cramer said it could be a $1.2 billion opportunity for the company.Shares of Exact Sciences have risen a hefty 83% in the last few weeks, and Cramer told viewers not to be greedy, while still saying that the stock is attractive ahead of an Oct. 29 conference where it will provide updates on its testing. Cramer said Exact Science should be considered a speculative stock, given that the company is likely to issue five million new shares in the coming months, and given that a 2012 approval is still a long way off. However, he said that the potential for this test is enormous, which makes the stock attractive.
Alcoa's TurnaroundIt's time to buy aluminum maker Alcoa (AA), Cramer told viewers in a sparkling outfit made from aluminum foil. He said Alcoa's quarterly results were not only a thing of beauty, they were also truly significant. Cramer said normally, the notion of Alcoa being a bellwether stock is simply ridiculous, but this quarter's conference call is a "must read." He said Alcoa painted a picture of end markets that are clearly on the upswing, including aerospace, automotive and even trucks and trailers, with strong demand being seeing around the globe, from Asia to Europe to South America. According to Cramer, the earnings estimates for the aluminum maker had simply gotten too low, making the company's six-cent-a-share earnings beat on revenue up 15% a cinch. He said the company has reduced its surplus, is seeing pricing holding firm and has earnings visibility for the first time in a long time. With shares of Alcoa trading at a 15% discount to their historical averages, Cramer said pointedly, "Alcoa doesn't belong this low."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV